Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia

This article was originally published in PharmAsia News

Executive Summary

TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division

You may also be interested in...



Merck Sells Dutch API Business To South Africa’s Aspen

Aspen Pharmacare continues a buying spree to boost its presence in Asia and Latin America.

India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs

The Indian drug maker has embarked on a new China strategy that includes biosimilars.

As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner

The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.

Related Content

UsernamePublicRestriction

Register

SC075652

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel